ClinicalTrials.gg
CompletedNCT00359138Updated Feb 9, 2022Results posted

The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)

A Phase 4 interventional study of desloratadine and levocetirizine in Hypersensitivity, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of the tested standardized allergenic extracts: tree pollen, cat dander, house dust mite, or a mixture of five grass pollens. Subjects will be randomized to desloratadine 5 mg once daily, levocetirizine 5mg once daily, or placebo once daily for 8 days of treatment followed by 11 days of skin testing after discontinuation of the antihistamine treatment phase. The duration of the suppressive effects of desloratadine on cutaneous allergen-induced wheal and flare responses after discontinuation of a one-week treatment will be established.

02

Conditions studied

  • Hypersensitivity

Browse trials for

Keywords

  • Histamine H1 Antagonists
  • Anti-Allergic Agents
03

In context

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

This study's enrollment of 36 is below the median of 73 across 692 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be 18 years of age or older, of either sex.
  • Subjects must have at least a history of positive skin testing to the allergens of tree pollen, grass pollen, house dust mite, or cat dander.
  • Non symptomatic volunteers allergic of different pollen they must be included out of the specific pollinic season.
  • Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Subjects must understand and be able to adhere to visit schedules
  • Subjects must be in general good health.
  • Women of must have a negative pregnancy test at Day -1 and must use an accepted method of during the entire duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have persistent asthma.
  • Subjects who have chronic urticaria or atopic dermatosis.
  • Subjects who have received any treatment listed below more recently than the indicated prior to Randomization, or who must continue to receive treatment as listed below.

Medications Prohibited During the Trial and Washout Period Prior to Visit 1

    • Intramuscular or intra-articular, 1 month
    • Oral, inhaled, intravenous, rectal, intranasal, or ocular, 7 days
    • High-potency dermatological, 7 days
  • Cromolyn/Lodoxamide/Nedocromil

    • Intranasal, ocular, inhaled, or oral, 2 days
  • Antihistamines

    • Long-acting prescription (eg, levocetirizine, fexofenadine, and desloratadine), 15 days
    • Short-acting (eg, chlorpheniramine, brompheniramine including over-the-counter [OTC] forms, hydroxyzine), 15 days
    • Ocular (eg, levocabastine), 15 days
  • Leukotriene inhibitors (eg, montelukast), 7 days
  • Systemic antibiotics, 14 days (the washout refers to antibiotics used to treat an upper or lower respiratory tract infection)
  • Immunotherapy (desensitization), 1 year
  • Decongestants

    • oral, 2 days
    • local, 2 days
  • Ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs; eg, Toradol), 5 days
  • medications, 30 days
  • Tricyclic antidepressants (eg, amitriptyline, clomipramine, doxepin, imipramine, trimipramine, amoxapine, desipramine, nortriptyline, protriptyline), 30 days
  • Tetracyclic antidepressants (eg, maprotiline, mirtazapine), 30 days

    • Subjects with a history of to desloratadine, to levocetirizine, or any of their .
    • Women who are breast-feeding, pregnant, or intend to become pregnant.
    • Subjects with any condition or situation, other than the condition being studied, that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
    • Subjects who have used any investigational drugs within 30 days of randomization.
    • Subjects working between 11 PM and 8 AM (night shift).
    • Subjects who have skin/color pigmentation incompatible with accurate measurements of flare reaction.
    • Subjects with cutaneous hyperactivity: negative prick test control >3 mm.
    • Subjects who are participating in any other clinical study.
    • Subjects who are part of the staff personnel directly involved with this study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Desloratadine 5 mg tablet + Levocetirizine placebo capsule

    Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).

    Drug: desloratadine · Drug: Levocetirizine placebo capsule

  • Active comparator
    Desloratadine placebo tablet + Levocetirizine 5 mg capsule

    Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).

    Drug: levocetirizine · Drug: Desloratadine placebo tablet

  • Placebo comparator
    Desloratadine placebo tablet + Levocetirizine placebo capsule

    Subject was instructed to take 1 tablet and 1 capsule, once daily from day one (visit 3) to day 8 (visit 4).

    Drug: Desloratadine placebo tablet · Drug: Levocetirizine placebo capsule

Interventions

  • 5 mg tablet once daily

  • 5 mg capsule once daily

  • DrugDesloratadine placebo tablet

    once daily

  • DrugLevocetirizine placebo capsule

    once daily

06

What researchers measure

Primary outcomes

  1. Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment

    The number of days after treatment discontinuation until a measurable wheal and flare response.

    Time frame: Starting at Day 8

07

Results

Posted Nov 1, 2010

Participant flow

Participant flow — Overall Study
MilestoneDesloratadine 5 mg Tablet + Levocetirizine Placebo CapsuleDesloratadine Placebo Tablet + Levocetirizine 5 mg CapsuleDesloratadine Placebo Tablet + Levocetirizine Placebo Capsule
Started121212
Completed121212
Not completed000

Outcome measures

PrimaryDuration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment

The number of days after treatment discontinuation until a measurable wheal and flare response.

Time frame:
Starting at Day 8
Reported as:
Mean · Days
Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment
DaysDesloratadine 5 mg Tablet + Levocetirizine Placebo CapsuleDesloratadine Placebo Tablet + Levocetirizine 5 mg CapsuleDesloratadine Placebo Tablet + Levocetirizine Placebo Capsule
Duration of Suppressive Effect of Desloratadine After Discontinuation of a 1-week Treatment5 ± 1.654 ± 1.60NA ± NA

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule—0/12 (0%)5/12 (41.7%)
Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule—0/12 (0%)4/12 (33.3%)
Desloratadine Placebo Tablet + Levocetirizine Placebo Capsule—0/12 (0%)1/12 (8.3%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventDesloratadine 5 mg Tablet + Levocetirizine Placebo CapsuleDesloratadine Placebo Tablet + Levocetirizine 5 mg CapsuleDesloratadine Placebo Tablet + Levocetirizine Placebo Capsule
SomnolenceNervous system disorders1/122/120/12
Abdominal Pain UpperGastrointestinal disorders1/120/120/12
Dry MouthGastrointestinal disorders0/121/120/12
NauseaGastrointestinal disorders1/121/120/12
VomitingGastrointestinal disorders0/121/120/12
AstheniaGeneral disorders1/121/120/12
RhinitisInfections and infestations0/121/121/12
Muscle ContractureMusculoskeletal and connective tissue disorders0/121/120/12
HeadacheNervous system disorders1/120/120/12
InsomniaPsychiatric disorders0/121/120/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Desloratadine 5 mg Tablet + Levocetirizine Placebo CapsuleDesloratadine Placebo Tablet + Levocetirizine 5 mg CapsuleDesloratadine Placebo Tablet + Levocetirizine Placebo CapsuleTotal
Mean23.42 ± 4.9128.33 ± 8.6928.83 ± 11.5526.86 ± 8.91
Sex: Female, Male
Sex: Female, Male(Participants)Desloratadine 5 mg Tablet + Levocetirizine Placebo CapsuleDesloratadine Placebo Tablet + Levocetirizine 5 mg CapsuleDesloratadine Placebo Tablet + Levocetirizine Placebo CapsuleTotal
Female58518
Male74718
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 4 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2006
First posted
Aug 1, 2006
Start
Feb 2006
Primary completionActual
May 2006
CompletionActual
May 2006
Results first posted
Nov 1, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00359138
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 1, 2006
Start date
Feb 2006
Primary completion
May 2006
Completion
May 2006
Results posted
Nov 1, 2010
Last update
Feb 9, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desloratadine

Start the discussion